<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ParagraphFour.com | gregoryglass | Activity</title>
	<link>https://paragraphfour.com/members/gregoryglass/activity/</link>
	<atom:link href="https://paragraphfour.com/members/gregoryglass/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for gregoryglass.</description>
	<lastBuildDate>Sat, 23 May 2026 01:15:52 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">ae79b48879b3971fc94fce2be3e7f9c3</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11941/</link>
				<pubDate>Fri, 22 May 2026 19:26:22 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11941"><a href="https://paragraphfour.com/activity/p/11941/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">be542a287e0bfb473ed9a8a1135cf81b</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11940/</link>
				<pubDate>Fri, 22 May 2026 19:25:39 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11940"><a href="https://paragraphfour.com/activity/p/11940/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">338e087e8b606af0a7b490c732a5440e</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Bryson-Hughes) &#039;: The Paragraph Four Report®
The Appellate Judges (Bryson - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11938/</link>
				<pubDate>Fri, 22 May 2026 19:01:42 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Bryson &#8211; Hughes)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11938"><a href="https://paragraphfour.com/activity/p/11938/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c3830ad47787019710fe4d2205854775</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11937/</link>
				<pubDate>Fri, 22 May 2026 18:59:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11937"><a href="https://paragraphfour.com/activity/p/11937/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e94e5b01a0875514f3ff9f8984b6b634</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11934/</link>
				<pubDate>Thu, 21 May 2026 14:32:48 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11934"><a href="https://paragraphfour.com/activity/p/11934/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a703d416b81d5cee4a55f481350b2721</guid>
				<title>gregoryglass updated &#039;Hetlioz®(tasimelteon) Capsules &#039;: Hetlioz®(tasimelteon) Capsules
Annual Sales  $76.7M [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11933/</link>
				<pubDate>Thu, 21 May 2026 14:29:57 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Hetlioz®(tasimelteon) Capsules</b><br />
<b>Annual Sales </b> $76.7M (product family)<br />
<b>Company </b> VANDA PHARMACEUTICALS<br />
<b>Date of First Filing</b> January 31, 2018</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> VANDA PHARMACEUTICALS INC v. TEVA PHARMACEUTICALS USA INC<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc) 23-1247<br />
<b>Date Filed:</b> 12/15/22<br />
<b>Judge: </b> Dyk&hellip;<span class="activity-read-more" id="activity-read-more-11933"><a href="https://paragraphfour.com/activity/p/11933/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">43ba5d6be9e8b6aa195784c603a44411</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11932/</link>
				<pubDate>Thu, 21 May 2026 13:53:53 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11932"><a href="https://paragraphfour.com/activity/p/11932/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dc9bfdbdcaa8822fd08777f579a74253</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11931/</link>
				<pubDate>Thu, 21 May 2026 13:53:08 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11931"><a href="https://paragraphfour.com/activity/p/11931/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b3f863120a5788182572119a57b7f671</guid>
				<title>gregoryglass updated &#039;Inter Partes Review List &#039;: The Paragraph Four Report®
Inter Partes Review List

In [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11929/</link>
				<pubDate>Thu, 21 May 2026 13:42:40 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Inter Partes Review List</b></p>
<p>In late 2012, the Inter Partes Review procedure went into effect allowing anyone to file a Petition with the US Patent and Trademark Office requesting that the USPTO invalidate an issued patent. Over time, this procedure became more common for Paragraph IV products and Orange Book Patents&hellip;<span class="activity-read-more" id="activity-read-more-11929"><a href="https://paragraphfour.com/activity/p/11929/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d7cb3d725a97ba502ea3fa18ecacf35d</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Prost &#8211; Reyna) &#039;: The Paragraph Four Report®
The Appellate Judges (Prost - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11928/</link>
				<pubDate>Thu, 14 May 2026 21:27:40 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Prost &#8211; Reyna)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the Federal&hellip;<span class="activity-read-more" id="activity-read-more-11928"><a href="https://paragraphfour.com/activity/p/11928/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3cbebac8e2bce5e60703657b988ff726</guid>
				<title>gregoryglass updated &#039;Paragraph IV Appellate Judges (Schall &#8211; Wallach) &#039;: The Paragraph Four Report®
The Appellate Judges (Schall - [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11927/</link>
				<pubDate>Thu, 14 May 2026 21:27:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>The Appellate Judges (Schall &#8211; Wallach)</b></p>
<p>This Section provides data on federal judges who preside in The Federal Circuit Court of Appeals. The Federal Circuit has exclusive appellate jurisdiction over Paragraph IV cases which means that a party that loses in the district court can only appeal the decision to the&hellip;<span class="activity-read-more" id="activity-read-more-11927"><a href="https://paragraphfour.com/activity/p/11927/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ad90bbe69f2725c46fb5c1f877326239</guid>
				<title>gregoryglass updated &#039;Court of Appeals Decisions &#8211; by Case Name &#039;: The Paragraph Four Report®
Court of Appeals Opinions by [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11926/</link>
				<pubDate>Thu, 14 May 2026 21:24:15 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report®</b><br />
<b>Court of Appeals Opinions by Case Name</b></p>
<p>Opinions from the Court of Appeals for the Federal Circuit can be found in several places in ParagraphFour.com. Each Opinion issued for a particular product can be found under the product name, and you can also see how each individual Appellate Judge ruled in their various&hellip;<span class="activity-read-more" id="activity-read-more-11926"><a href="https://paragraphfour.com/activity/p/11926/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">30b37e785fa74f9e8d2a8e3ee67331b3</guid>
				<title>gregoryglass updated &#039;Veletri®(epoprostenol) Injection &#039;: Veletri®(epoprostenol) Injection
Company  ACTELION
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11925/</link>
				<pubDate>Thu, 14 May 2026 21:17:32 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Veletri®(epoprostenol) Injection</b><br />
<b>Company </b> ACTELION<br />
<b>Date of First Filing</b> March 31, 2017</p>
<p><b>Paragraph IV Applicant:</b> Sun<br />
<b>Case Name: </b> ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES INC et al<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2017cv05015<br />
<b>Date Filed:</b> 7/7/17<br />
<b>Judge: </b> Sheridan<br />
<b>Product Strength:</b> 1.5mg/vial and&hellip;<span class="activity-read-more" id="activity-read-more-11925"><a href="https://paragraphfour.com/activity/p/11925/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cb2c59f58c37d6b7dbe1c4fe6efa6828</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11923/</link>
				<pubDate>Wed, 13 May 2026 14:01:22 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11923"><a href="https://paragraphfour.com/activity/p/11923/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d18243cc4afec7dcbfd97eb241dd4957</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11921/</link>
				<pubDate>Fri, 08 May 2026 16:00:20 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11921"><a href="https://paragraphfour.com/activity/p/11921/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d817224142fc58ad990953ec75d48187</guid>
				<title>gregoryglass updated &#039;Xifaxan®(rifaximin) Tablets &#039;: Xifaxan®(rifaximin) Tablets
Company  SALIX
Date of First [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11920/</link>
				<pubDate>Fri, 08 May 2026 15:59:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xifaxan®(rifaximin) Tablets</b><br />
<b>Company </b> SALIX<br />
<b>Date of First Filing</b> December 18, 2015 and January 28, 2019 (200mg)</p>
<p><b>Paragraph IV Applicant:</b> Actavis<br />
<b>Case Name: </b> SALIX PHARMACEUTICALS LTD et al v. ACTAVIS LABORATORIES FL INC<br />
<b>Court/Case #: </b> Delaware District Court (dedc) 1:2016cv00188<br />
<b>Date Filed:</b> 3/23/16<br />
<b>Judge: </b> Sleet<br />
<b>Product Strength:</b> 550&hellip;<span class="activity-read-more" id="activity-read-more-11920"><a href="https://paragraphfour.com/activity/p/11920/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ed1af2bea179aa67054246c9eb8546cf</guid>
				<title>gregoryglass updated &#039;Injectafer®(ferric carboxymaltose) Injection &#039;: Injectafer®(ferric carboxymaltose) Injection 
Company  VIFOR [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11919/</link>
				<pubDate>Tue, 05 May 2026 15:35:56 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Injectafer®(ferric carboxymaltose) Injection </b><br />
<b>Company </b> VIFOR INTERNATIONAL<br />
<b>Date of First Filing</b> March 27, 2019 and February 22, 2024 (50 mg/10 mL)</p>
<p><b>Paragraph IV Applicant:</b> Mylan<br />
<b>Case Name: </b> VIFOR (INTERNATIONAL) AG et al v. MYLAN LABORATORIES LTD<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2019cv13955<br />
<b>Date Filed:</b> 6/18/19<br />
<b>Judge: </b> Wolfs&hellip;<span class="activity-read-more" id="activity-read-more-11919"><a href="https://paragraphfour.com/activity/p/11919/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">572853b67d4eb25b283d207dac3a0190</guid>
				<title>gregoryglass updated &#039;Invega Sustenna®(paliperidone) ER Inj Suspension &#039;: Invega Sustenna®(paliperidone) Extended-release Injectable [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11917/</link>
				<pubDate>Tue, 05 May 2026 15:08:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Invega Sustenna®(paliperidone) Extended-release Injectable Suspension</b><br />
<b>Annual Sales </b> $3.1B (product family)<br />
<b>Company </b> JANSSEN<br />
<b>Date of First Filing</b> November 21, 2017</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> JANSSEN PHARMACEUTICALS INC et al v. TEVA PHARMACEUTICALS USA INC et al<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc)&hellip;<span class="activity-read-more" id="activity-read-more-11917"><a href="https://paragraphfour.com/activity/p/11917/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8775a9aefe2e1c120cb56c3efe1ea953</guid>
				<title>gregoryglass updated &#039;Last Month&#8217;s Paragraph IV Highlights &#039;: April 2026</title>
				<link>https://paragraphfour.com/activity/p/11916/</link>
				<pubDate>Fri, 01 May 2026 16:59:31 -0400</pubDate>

									<content:encoded><![CDATA[<p>April 2026</p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">389d7ae4f501e0a875281951f97cffc4</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11913/</link>
				<pubDate>Fri, 01 May 2026 16:30:23 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11913"><a href="https://paragraphfour.com/activity/p/11913/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6ada29cb221ce544bee1bbe83e533fce</guid>
				<title>gregoryglass updated &#039;OxyContin®(oxycodone) ER Tabs (NDA 22-272) Part 2 &#039;: OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11900/</link>
				<pubDate>Fri, 01 May 2026 12:18:03 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>OxyContin®(oxycodone) Extended-release Tablet (NDA 22-272) Part 2</b><br />
<b>Company </b> PURDUE<br />
<b>Date of First Filing</b> October 4, 2010 (40mg), October 18, 2010 (30, 60, and 90mg), October 25, 2010 (10mg), October 28, 2010 (15mg), and October 29, 2010 (20mg).</p>
<p><b>Editor&#8217;s Note</b> This Product Topic covers the fifth set of cases filed on this product since 2001.&hellip;<span class="activity-read-more" id="activity-read-more-11900"><a href="https://paragraphfour.com/activity/p/11900/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6f6ed6ec05737f7fd5b3186e2c51cef1</guid>
				<title>gregoryglass updated &#039;Xarelto®(rivaroxaban) Tablets &#039;: Xarelto®(rivaroxaban) Tablets
Annual Sales  $2.36B (as [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11899/</link>
				<pubDate>Thu, 30 Apr 2026 22:12:48 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xarelto®(rivaroxaban) Tablets</b><br />
<b>Annual Sales </b> $2.36B (as reported by J&amp;J)<br />
<b>Company </b> BAYER (JANSSEN)<br />
<b>Date of First Filing</b> July 1, 2015 and November 15, 2018 (2.5mg)</p>
<p><b>Special Note 1:</b> On 10/9/15, Bayer filed its PIV case against 7 ANDA filers (Aurobindo through Torrent). Bayer included all three patents against all of the defendants except where&hellip;<span class="activity-read-more" id="activity-read-more-11899"><a href="https://paragraphfour.com/activity/p/11899/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cbc7015de52a56ce99216d3f37c76188</guid>
				<title>gregoryglass updated &#039;Jakafi®(ruxolitinib) Tablets &#039;: Jakafi®(ruxolitinib) Tablets 
Annual Sales  $2.79B
Company [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11892/</link>
				<pubDate>Thu, 30 Apr 2026 21:04:32 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Jakafi®(ruxolitinib) Tablets </b><br />
<b>Annual Sales </b> $2.79B<br />
<b>Company </b> INCYTE<br />
<b>Date of First Filing</b> December 17, 2015</p>
<p><b>Special Note:</b> After this product received its first PIV Notice in 2015, Incyte did not file any PIV cases until 2024 when a case against Apotex. We had placed this product as a &#8220;No Litigation Pending&#8221; product, and we keep that entry&hellip;<span class="activity-read-more" id="activity-read-more-11892"><a href="https://paragraphfour.com/activity/p/11892/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ad5f3f9f254072b34cd29a95975fc870</guid>
				<title>gregoryglass updated &#039;Injectafer®(ferric carboxymaltose) Injection &#039;: Injectafer®(ferric carboxymaltose) Injection 
Company  VIFOR [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11891/</link>
				<pubDate>Thu, 30 Apr 2026 20:59:15 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Injectafer®(ferric carboxymaltose) Injection </b><br />
<b>Company </b> VIFOR INTERNATIONAL<br />
<b>Date of First Filing</b> March 27, 2019 and February 22, 2024 (50 mg/10 mL)</p>
<p><b>Paragraph IV Applicant:</b> Mylan<br />
<b>Case Name: </b> VIFOR (INTERNATIONAL) AG et al v. MYLAN LABORATORIES LTD<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2019cv13955<br />
<b>Date Filed:</b> 6/18/19<br />
<b>Judge: </b> Wolfs&hellip;<span class="activity-read-more" id="activity-read-more-11891"><a href="https://paragraphfour.com/activity/p/11891/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e29fb9197ad3781bb807fc61e727e6b8</guid>
				<title>gregoryglass updated &#039;Farxiga®(dapagliflozin) Tablets and dapagliflozin combination products &#039;: Farxiga®(dapagliflozin) Tablets 
Xigduo [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11889/</link>
				<pubDate>Thu, 30 Apr 2026 20:06:00 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Farxiga®(dapagliflozin) Tablets </b><br />
<b>Xigduo XR®(dapagliflozin/metformin) Extended-release Tablets</b><br />
<b>Qtern®(dapagliflozin/saxagliptin) Tablets </b><br />
<b>Company </b> ASTRAZENECA<br />
<b>Product Sales:</b> $1.75B<br />
<b>Date of First Filing</b> January 8, 2018 (Farxiga); October 29, 2018 (Xigduo XR); July 29, 2020 (Qtern)</p>
<p><b>Special Note:</b> After the sole case against Farxiga settled wi&hellip;<span class="activity-read-more" id="activity-read-more-11889"><a href="https://paragraphfour.com/activity/p/11889/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b919e6bbdb4f116d5a06613be97336e0</guid>
				<title>gregoryglass updated &#039;Belrapzo®(bendamustine) Injection &#039;: Belrapzo®(bendamustine) Injection
Company  EAGLE
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11882/</link>
				<pubDate>Thu, 30 Apr 2026 18:32:19 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Belrapzo®(bendamustine) Injection</b><br />
<b>Company </b> EAGLE<br />
<b>Date of First Filing</b> Not applicable/reported by FDA</p>
<p><b>Paragraph IV Applicant:</b> Slayback<br />
<b>Case Name: </b> EAGLE PHARMACEUICALS INC v. SLAYBACK PHARMA LLC<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc) 19-1924<br />
<b>Date Filed:</b> 5/24/19<br />
<b>Judge: </b> O&#8217;Malley, Reyna, Chen<br />
<b>Product Strength:</b>&hellip;<span class="activity-read-more" id="activity-read-more-11882"><a href="https://paragraphfour.com/activity/p/11882/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0734247ca0264cc8efa0185ab0c59999</guid>
				<title>gregoryglass updated &#039;Adzenys XR- ODT®(amphetamine) ER ODT &#039;: Adzenys XR- ODT®(amphetamine) Extended-release Orally [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11881/</link>
				<pubDate>Thu, 30 Apr 2026 18:24:53 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Adzenys XR- ODT®(amphetamine) Extended-release Orally Disintegrating Tablets</b><br />
<b>Company </b> NEOS THERAPEUTICS<br />
<b>Date of First Filing</b> May 10, 2016</p>
<p><b>Paragraph IV Applicant:</b> Actavis<br />
<b>Case Name: </b> NEOS THERAPEUTICS INC et al v. ACTAVIS LABORATORIES FL INC et al<br />
<b>Court/Case #: </b> Delaware District Court (dedc) 1:2016cv00766<br />
<b>Date Filed:</b> 9/1/16<br />
<b>Judge: </b><br />
<b>Produc&hellip;</b><span class="activity-read-more" id="activity-read-more-11881"><a href="https://paragraphfour.com/activity/p/11881/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">fadda50ab09f274888c20d5f62ec5108</guid>
				<title>gregoryglass updated &#039;Vasostrict®(vasopressin) Injection &#039;: Vasostrict®(vasopressin) Injection
Company  PAR
Date of [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11880/</link>
				<pubDate>Wed, 29 Apr 2026 19:08:31 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Vasostrict®(vasopressin) Injection</b><br />
<b>Company </b> PAR<br />
<b>Date of First Filing</b> March 23, 2018 (20 units/mL, 1 mL) and June 29, 2018 (20 units/mL, 10 mL) and February 28, 2022 (40 units/100 mL and 60 units/100 mL) and December 20, 2022 (20 units/100 mL) </p>
<p><b>Paragraph IV Applicant:</b> Eagle<br />
<b>Case Name: </b> PAR PHARMACEUTICAL INC et al v. EAGLE PHARMACEUTICALS,&hellip;<span class="activity-read-more" id="activity-read-more-11880"><a href="https://paragraphfour.com/activity/p/11880/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">79bb1c468537f085d256b633947073fb</guid>
				<title>gregoryglass updated &#039;Invega Sustenna®(paliperidone) ER Inj Suspension &#039;: Invega Sustenna®(paliperidone) Extended-release Injectable [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11863/</link>
				<pubDate>Wed, 29 Apr 2026 14:55:14 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Invega Sustenna®(paliperidone) Extended-release Injectable Suspension</b><br />
<b>Annual Sales </b> $3.1B (product family)<br />
<b>Company </b> JANSSEN<br />
<b>Date of First Filing</b> November 21, 2017</p>
<p><b>Paragraph IV Applicant:</b> Teva<br />
<b>Case Name: </b> JANSSEN PHARMACEUTICALS INC et al v. TEVA PHARMACEUTICALS USA INC et al<br />
<b>Court/Case #: </b> Court of Appeals for the Federal Circuit (cafc)&hellip;<span class="activity-read-more" id="activity-read-more-11863"><a href="https://paragraphfour.com/activity/p/11863/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b80374f5d799acacc0596a76de6ebbed</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11855/</link>
				<pubDate>Tue, 28 Apr 2026 14:24:33 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11855"><a href="https://paragraphfour.com/activity/p/11855/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0a0df52d6bae9ebd2b3dd02a560b1382</guid>
				<title>gregoryglass updated &#039;Xarelto®(rivaroxaban) Tablets &#039;: Xarelto®(rivaroxaban) Tablets
Annual Sales  $2.36B (as [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11854/</link>
				<pubDate>Tue, 28 Apr 2026 14:23:39 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Xarelto®(rivaroxaban) Tablets</b><br />
<b>Annual Sales </b> $2.36B (as reported by J&amp;J)<br />
<b>Company </b> BAYER (JANSSEN)<br />
<b>Date of First Filing</b> July 1, 2015 and November 15, 2018 (2.5mg)</p>
<p><b>Special Note 1:</b> On 10/9/15, Bayer filed its PIV case against 7 ANDA filers (Aurobindo through Torrent). Bayer included all three patents against all of the defendants except where&hellip;<span class="activity-read-more" id="activity-read-more-11854"><a href="https://paragraphfour.com/activity/p/11854/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">15f7455851860b988cf784d475d532dd</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11852/</link>
				<pubDate>Sat, 25 Apr 2026 14:48:13 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11852"><a href="https://paragraphfour.com/activity/p/11852/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">50c07935a0b27dde522e352f6c16c4b3</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11849/</link>
				<pubDate>Thu, 23 Apr 2026 17:10:31 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11849"><a href="https://paragraphfour.com/activity/p/11849/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7064ba5e9b6c9b3e6e8167aa7f2e4982</guid>
				<title>gregoryglass updated &#039;Bromsite(r)(bromfenac) Ophthalmic Solution &#039;: Bromsite(r)(bromfenac) Ophthalmic Solution 
Company  SUN [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11848/</link>
				<pubDate>Thu, 23 Apr 2026 17:09:12 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Bromsite(r)(bromfenac) Ophthalmic Solution </b><br />
<b>Company </b> SUN<br />
<b>Date of First Filing</b> October 25, 2017</p>
<p><b>Paragraph IV Applicant:</b> Lupin<br />
<b>Case Name: </b> SUN PHARMA GLOBAL FZE et al v. LUPIN LIMITED et al<br />
<b>Court/Case #: </b> New Jersey District Court (njdc) 3:2018cv02213<br />
<b>Date Filed:</b> 2/15/18<br />
<b>Judge: </b> Wolfson<br />
<b>Product Strength:</b> 0.075%<br />
<b>Litigated Patents&hellip;</b><span class="activity-read-more" id="activity-read-more-11848"><a href="https://paragraphfour.com/activity/p/11848/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4fa8e48371d739713f67529652deb22f</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11845/</link>
				<pubDate>Tue, 21 Apr 2026 20:08:44 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11845"><a href="https://paragraphfour.com/activity/p/11845/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6be446b180bc636cac4ef36366f63f4e</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11843/</link>
				<pubDate>Tue, 21 Apr 2026 19:49:12 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11843"><a href="https://paragraphfour.com/activity/p/11843/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e0a03c22f246227ce87b9bfb16628b82</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11842/</link>
				<pubDate>Tue, 21 Apr 2026 19:48:41 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11842"><a href="https://paragraphfour.com/activity/p/11842/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">804fd3de7bea3ce8d5ebbac494aab81f</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11841/</link>
				<pubDate>Tue, 21 Apr 2026 19:47:43 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11841"><a href="https://paragraphfour.com/activity/p/11841/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f5ff90cfcb287f1d08aa427fbdbe8d08</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11839/</link>
				<pubDate>Fri, 17 Apr 2026 17:35:00 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11839"><a href="https://paragraphfour.com/activity/p/11839/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8048a19e9857ae82ade66f91e27624ef</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11837/</link>
				<pubDate>Fri, 17 Apr 2026 17:00:08 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11837"><a href="https://paragraphfour.com/activity/p/11837/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6e15884e87624c6c0ff12aea09034259</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11834/</link>
				<pubDate>Tue, 14 Apr 2026 15:03:46 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11834"><a href="https://paragraphfour.com/activity/p/11834/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">72b9501bbd8270ba72436cc6c33c3217</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11832/</link>
				<pubDate>Tue, 14 Apr 2026 14:47:43 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11832"><a href="https://paragraphfour.com/activity/p/11832/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a99ffcc30d76a5fb538e708c1a6a3881</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11828/</link>
				<pubDate>Mon, 13 Apr 2026 14:54:29 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11828"><a href="https://paragraphfour.com/activity/p/11828/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0f3d4763e0cc1e275980b1cff094968c</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11826/</link>
				<pubDate>Mon, 13 Apr 2026 14:51:37 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11826"><a href="https://paragraphfour.com/activity/p/11826/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c4a80a3ce7a3c46603649b97480e5f70</guid>
				<title>gregoryglass updated &#039;Janumet XR®(sitagliptin and metformin) ER Tabs &#039;: Janumet XR®(sitagliptin and metformin) Extended Release [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11825/</link>
				<pubDate>Mon, 13 Apr 2026 14:50:50 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Janumet XR®(sitagliptin and metformin) Extended Release Tablets </b><br />
<b>Annual Sales </b><br />
<b>Company </b> MERCK<br />
<b>Date of First Filing </b> March 16, 2012 (50mg/500mg and 50mg/1,000mg) and October 22, 2012 (100mg/1,000mg)</p>
<p><b>Special Note:</b> When the ANDA filer(s) filed their ANDA’s, Merck did not bring any PIV actions. As such, this product topic was listed as a “N&hellip;<span class="activity-read-more" id="activity-read-more-11825"><a href="https://paragraphfour.com/activity/p/11825/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">80fd12ccf2052aed42c1436fb8f725c8</guid>
				<title>gregoryglass updated &#039;Synjardy®(empagliflozin/met&#8230;) Tabs and XR® &#039;: Synjardy®(empagliflozin and metformin) Tablets 
Synjardy [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11823/</link>
				<pubDate>Mon, 13 Apr 2026 14:36:15 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>Synjardy®(empagliflozin and metformin) Tablets </b><br />
<b>Synjardy XR®(empagliflozin and metformin) Extended-release Tablets</b><br />
<b>Company </b> BOEHRINGER INGELHEIM<br />
<b>Date of First Filing</b> August 1, 2018</p>
<p><b>Special Note:</b> When these cases were filed, several of them also involve the monotherapy product Jardiance®(empagliflozin) Tablets and combination therapy Gl&hellip;<span class="activity-read-more" id="activity-read-more-11823"><a href="https://paragraphfour.com/activity/p/11823/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">913feb4ce28b5dacdef201eae931c0f2</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #3 (Q-Z) &#039;: The Paragraph Four Report ®
Generic Companies Report #3 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11822/</link>
				<pubDate>Mon, 13 Apr 2026 14:34:42 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #3 (Q-Z)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11822"><a href="https://paragraphfour.com/activity/p/11822/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dd3c07ca576b87aff04e24b78fdbb3dd</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #2 (F-P) &#039;: The Paragraph Four Report ®
Generic Companies Report #2 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11821/</link>
				<pubDate>Mon, 13 Apr 2026 14:32:40 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #2 (F-P)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11821"><a href="https://paragraphfour.com/activity/p/11821/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">02bc238b5c80fb1b8db5c35d8c2be5a5</guid>
				<title>gregoryglass updated &#039;Generic Companies Report #1 (A-E) &#039;: The Paragraph Four Report ®
Generic Companies Report #1 [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11820/</link>
				<pubDate>Mon, 13 Apr 2026 14:27:24 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Generic Companies Report #1 (A-E)</b></p>
<p><b>List of Companies and Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (only when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1,&hellip;<span class="activity-read-more" id="activity-read-more-11820"><a href="https://paragraphfour.com/activity/p/11820/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f5a2af8d526905f1022bb1e921dd9c28</guid>
				<title>gregoryglass updated &#039;Branded Companies Report &#039;: The Paragraph Four Report ®
Branded Companies [&#133;]</title>
				<link>https://paragraphfour.com/activity/p/11819/</link>
				<pubDate>Mon, 13 Apr 2026 14:22:10 -0400</pubDate>

									<content:encoded><![CDATA[<p><b>The Paragraph Four Report ®<br />
Branded Companies Report</b></p>
<p><b>List of Companies with Products under active Paragraph IV Certification</b><br />
Data includes total number and product and includes products that do not have a lawsuit filed (when verified by other sources). An Asterisk (*) indicates an &#8220;Old Case&#8221; (terminated after November 1, 2003)</p>
<p><b>ABBOTT LAB&hellip;</b><span class="activity-read-more" id="activity-read-more-11819"><a href="https://paragraphfour.com/activity/p/11819/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>